5. 510(K) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

Date Prepared: December 4, 2008

Applicant Information:
Lipose Corp.
280 Railroad Ave., Suite 200
Greenwich, CT 06830

Device Information:

<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Lipose Fat Transfer System</th>
</tr>
</thead>
<tbody>
<tr>
<td>Classification</td>
<td>Class II 21CFR 878.5040</td>
</tr>
<tr>
<td>Product Code</td>
<td>MUU</td>
</tr>
<tr>
<td>Classification Name</td>
<td>Liposuction Cannula</td>
</tr>
</tbody>
</table>

Physical Description:
The Lipose Fat Transfer System is a single-use disposable kit used in aspiration, harvesting, filtering, and transferring of autologus fat. The Lipose Fat Transfer System simplifies the collection and transfer autologous fat used in body contouring. The materials that comprise the Lipose Fat Transfer System are used routinely in similar devices and the predicate devices.

Intended Use:
The Lipose Fat Transfer System is intended to be used in the aspiration, harvesting, filtering and reinjecting of autologous fat.

Equivalent Device:
The subject device is substantially equivalent in intended use/technological characteristics and/or method of operation to:

- Tissu-Trans™ Syringe (K050797)
- Tulip Disposable Cannulas (K060089)
- Cytori AFT System (K072587)
- Genesis Biosystems, Lipivage™ Fat Harvest, Wash and Transfer System (K# unknown)
Summary:

Based on the intended use, materials, and technological characteristics information provided in this notification, the subject device has been shown to be substantially equivalent to the currently marketed predicate devices.
Lipose Corporation
% Mr. Alan Curtis, RAC
2647 Lin Gate Court
Pleasanton, California 94566

Re: K081848
Trade/Device Name: Lipose Fat Transfer System
Regulation Number: 21 CFR 878.5040
Regulation Name: Suction liopoplasty system
Regulatory Class: II
Product Code: MUU
Dated: October 23, 2008
Received: October 24, 2008

Dear Mr. Curtis:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health’s (CDRH’s) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH’s Office of Surveillance and Biometric’s (OSB’s) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson
Director
Division of General, Restorative and Neurological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
4. INDICATIONS FOR USE STATEMENT

510(k) Number (if known): ____________________________

Device Name: ____________________________ Lipose Fat Transfer System

Indications for Use:

The Lipose Fat Transfer System is intended to be used in the aspiration, harvesting, filtering and reinjecting of autologous fat.

Prescription Use [ ] AND/OR Over-The-Counter Use [ ]
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Page 1 of 1

Division of General, Restorative, and Neurological Devices

510(k) Number: USPSYR